A recent Executive Order (EO) de-risks psychedelic drug development by clarifying regulations, but scalable treatment models ...

Healthcare systems must turn proven research into patient care faster with practical infrastructure, product champions, trust ...

A “Godzilla” El Niño could disrupt pharma supply chains, pushing life sciences firms toward AI-driven weather forecasting, ...

What happened at BIO? This selected coverage from the BIO 2026 meeting in San Francisco includes highlights from panels on ...

Achieving regulatory approval for a new drug is an extraordinary achievement. The bar for success is high. Many companies with breakthrough scientific discoveries and promising clinical data still ...

Biotech has entered a new era of financial discipline. The days of easy capital, billion-dollar preclinical valuations, and “platform first, data later” investing have largely disappeared. Today, ...

Drug and device manufacturers have long sought clearer rules for sharing scientific information about unapproved (off-label) uses of their products with health care providers (“HCPs”). In January 2025 ...

The era of outsourced regulatory work and rented thinking is ending. Agentic AI makes in-house capability inevitable, if leadership has the nerve to build it. Every biopharma CEO now claims to run an ...

For much of the past two decades, the geography of pharmaceutical innovation was relatively stable. Discovery and capital clustered in hubs such as Boston, San Diego, and Basel. Asia played an ...

Europe produces extraordinary science. From RNA biology to immunology, many of the breakthroughs shaping modern medicine originate in European labs. But building a company around that science — ...

The global pharmaceutical industry is experiencing a multi-layered cost escalation across APIs, excipients, polymers, clinical logistics, and laboratory consumables in Q1 2026. This escalation follows ...

Speed alone no longer guarantees success; here’s what matters most in today’s launch environment. In today’s launch environment, order of entry (OOE) isn’t destiny. Many brands still anchor strategy ...